Back
Gilead Sciences, Inc. (GILD)
BiotechnologyGILD · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$135.82
−0.40%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$6.78
ROE
43.4%
Gross margin
79.4%
Debt/Equity
0.95x
Revenue growth
4.4%
Gilead Sciences, Inc. — company intelligence
Earnings surprises
Q1 2026$2.03 vs $1.95 est+4.0%
Q4 2025$1.86 vs $1.85 est+0.7%
Q3 2025$2.47 vs $2.17 est+13.7%
Q2 2025$2.01 vs $2.00 est+0.6%
Analyst consensus · 39 analysts
32 Buy7 Hold0 Sell
Updated Jul 5, 2026
Insider activity · 90 days
16 buys22 sellsnet -27,425 shares
Mercier JohannaSell 450 · Jun 15, 2026
Mercier JohannaSell 1,070 · Jun 15, 2026
Dickinson Andrew DSell 3,000 · Jun 15, 2026
Recent SEC filings
4 — Insider transaction reportJul 2, 2026
4 — Insider transaction reportJun 16, 2026
4 — Insider transaction reportJun 16, 2026
Latest news
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts — Yahoo · 13h ago
Is Gilead Sciences (GILD) Cheap With Trodelvy And Yeztugo In Focus? — Yahoo · 1d ago
Gilead Sciences (GILD) After Russell Growth Index Removal And A Fully Valued Narrative — Yahoo · 2d ago
Morgan Stanley Keeps Buy Rating on Gilead (GILD) — Yahoo · 2d ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Gilead Sciences, Inc.
Weekly undervalued picks (like GILD)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.